

Iressa[®] (gefitinib) – First-time generic

- On May 3, 2023, Ingenus launched an [AB-rated](#) generic version of AstraZeneca's [Iressa \(gefitinib\)](#) tablets.
 - [Apotex](#) and [Actavis/Teva](#) received FDA approval of AB-rated generic versions of Iressa on September 23, 2022 and April 26, 2023, respectively. Launch plans for these two generics are pending.
- Iressa is approved for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.